AMENDMENTS TO THE CLAIMS:

Please amend Claims 1 – 12 as follows:

1) (Original) Method of analysis of the tumor aggressivity of cancerous cells consisting of the measurement of the quantity of polymerized actin in the steady state in a lysate of the said cells.

2) (Currently Amended) Method according to claim 1, ~~characterized by the fact that~~ wherein the measurement carried out on the lysate is compared to one or more reference values of the quantity of polymerized actin in the steady state ~~i.e., in the cells in a culture specific to a phenotype i.e., in the tissues taken from biological samples~~.

3) (Currently Amended) Method according to ~~one of the claims 1 or 2~~ claim 1, ~~characterized by the fact that~~ wherein the quantity of polymerized actin corresponds to the sum of all the F-form actin.

4) (Currently Amended) Method according to ~~one of the claims 1 to 3~~ claim 2, ~~characterized by the fact that~~ wherein the measurement of the quantity of actin in the steady state is carried out by static fluorescence polarization in the presence of actin monomers bound to a fluorochrome, the monomers being incorporated into the actin filaments (actin F) formed during the endogenous actin polymerization of the lysate.

5) (Currently Amended) Method according to claim 4, ~~characterized by the fact that~~ wherein the actin monomers bound to a fluorochrome are added to the cellular lysate in a proportion ranging between 1/80th and 1/1600th in relation to the quantity of endogenous actin.

6) (Currently Amended) Method according to ~~one or the other of the preceding claims, characterized in that it includes~~ claim 1, including:

- the lysis of cancerous cells in non-denaturing conditions for the proteins, and the elimination of cellular debris,

- the total dosage of proteins in the lysate,

- the addition of actin monomers bound to a fluorochrome,

- the addition of substances necessary for the endogenous actin polymerization and the protection of the lysate proteins,

- the measurement of the quantity of polymerized actin in the steady state in the lysate.

7) (Currently Amended) Method of identification of molecules likely to present an anti-cancer activity, ~~characterized in that it includes the implementation of~~ comprising implementing a method according to one ~~or the other~~ of claims 1 to 6 in the presence of an appropriate quantity of the said molecule, and ~~that~~ determining the capacity of the said substance to restore a quantity of polymerized actin in the steady state corresponding to that of non-aggressive cells is determined.

8) (Currently Amended) Application of the method according to one ~~or~~ ~~the other~~ of claims 1 to 6 to the evaluation of the invasive character of the said cells.

9) (Currently Amended) Application of the method according to one ~~or~~ ~~the other~~ of claims 1 to 6 to the evaluation of the oncogenicity of the said cells.

10) (Currently Amended) Application of the method according to one ~~or~~ ~~the other~~ of claims 1 to 6 to the prediction of the sensitivity of the said cells to an anti-cancer treatment.

11) (Currently Amended) Application according to claim 10, ~~characterized in that~~ wherein the said anti-cancer treatment consists of radiotherapy or chemotherapy.

12) (Currently Amended) A kit for the implementation of a method according to one ~~or the other~~ of claims 1 to [[7]] 6, ~~characterized in that it includes;~~ including:

- a cell re-suspension medium for the cell lysis,

- the substances necessary for the endogenous actin polymerization and the protection of the lysate proteins,

- a solution of actin monomers bound to a fluorochrome,

- an actin polymerization tampon,

- a general actin tampon,

- possibly the extracts of aggressive and non-aggressive reference cells.